Filing Flows › Pulmonx (LUNG) › R&D spending
Pulmonx (LUNG) R&D spending by quarter
Pulmonx's R&D spending was $4.9M in Q3 2026 (third quarter 2026), -3% from Q2 2026. Over the last 7 quarters it ranged from $4.6M (Q4 2025) to $5.3M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.9M | -3% | +0.4% |
| Q2 2026 | $5.0M | +3% | -5% |
| Q1 2026 | $4.9M | +7% | +3% |
| Q4 2025 | $4.6M | -5% | — |
| Q3 2025 | $4.8M | -9% | — |
| Q2 2025 | $5.3M | +12% | — |
| Q1 2025 | $4.8M | — | — |
Q3 2026 at a glance
Pulmonx, Q3 2026: revenue $22.8M (+6% year over year), operating margin -32.8%, net loss $8.4M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Pulmonx's R&D spending?
Pulmonx's R&D spending was $4.9M in Q3 2026 (third quarter 2026), -3% from Q2 2026.
How has Pulmonx's R&D spending changed?
Over the last 7 quarters it ranged from $4.6M (Q4 2025) to $5.3M (Q2 2025).